Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study

Morifuji M, Higashi S, Ebihara S, Nagata M · GeroScience

NULL on the primary endpoint — the stepping test showed no difference at 4 or 12 weeks. Among secondary endpoints, 4-metre walking time was shorter than placebo at 12 weeks (the placebo group's time worsened), blood NAD+ and its metabolites rose, and PSQI scores for daytime dysfunction (p=0.010) and global sleep quality (p=0.013) improved.

Population

Older adults, 30 per arm

Intervention

NMN 250 mg/day for 12 weeks

Comparator

Placebo

Limitations

The title reports secondary endpoints; the primary endpoint was null. Funded entirely by Meiji Holdings, and three of the four authors are Meiji employees. The walking-speed difference arose partly because placebo deteriorated rather than NMN improving.